Disease relevance of LINS1

• The following were done: routine pulmonary function testing, measurements of elastic recoil (Pel), tidal breathing patterns, inspiratory work of breathing (Winsp), construction of static recoil-maximum flow curves, and measurement of baseline and transitional dyspnea index (TDI) [1].
• The phosphate solution prepared from sodium dihydrogen phosphate (NaH2PO4), containing 13 mg/ml phosphate and 0.5 meq/ml sodium, in the dosage 2.5-3.0 mg phosphate/Kg body weight, was administered through the central venous lins every 6-8 hours [2].

High impact information on LINS1

• There are important differences between LINS and oral neuroleptics that affect their pharmacokinetics [3].
• Human WINS1 mRNA of 2.8-kb in size was expressed in adult testis, prostate, spleen, thymus, skeletal muscle, fetal kidney and brain [4].

Analytical, diagnostic and therapeutic context of LINS1

• By avoiding first pass metabolism in gut and liver, LINS result in lower circulating concentrations of metabolites than are found after oral administration [3].
• The authors review the literature regarding the pharmacokinetics of long-acting injectable neuroleptic drugs (LINS) [3].

References